Forty patients with atrial fibrillation (AF), 23 patients with ventricular extrasystoles (VES), and 11 patients with various arrhythmias (VA) were treated with amiodarone (0.2-0.6 g/day). Suppression of arrhythmia was 67.5% in AF, 78.2% in VES, and 81.8% in others with VA. Median age of converted patients was higher than that of nonconverted. The duration of AF before treatment was inversely related to drug efficacy. Average time needed for conversion was 6-8 days of treatment. Plasma amiodarone concentration at the day of conversion did not differ from that of nonconverted patients. Amiodarone concentration levels off after the 8th day of treatment, whereas that of the metabolite increases with time of treatment. Biologic half-life of plasma amiodarone after discontinuation of treatment varied, but was higher than 4 days. The percent of decline of the metabolite concentration was lower than that of the parent drug.
Download full-text PDF |
Source |
|---|
Publication Analysis
Top Keywords
Similar Publications
Sodium glucose co-transporter 2 (SGLT2) inhibitors versus dipeptidyl peptidase-4 (DPP-4) inhibitors and the risk of Atrial Fibrillation in patients with type 2 diabetes mellitus: a meta-analysis.
BMC Cardiovasc Disord
January 2025
The second Affiliated Hospital of Xi'an Jiaotong University, Xinjiang Hospital (People's Hospital of Xinjiang Uygur Autonomous Region, Bainiaohu Hospital), Urumqi, Xinjiang, 830026, People's Republic of China.
Background: Several studies showed higher risks of cardiovascular complications to have been observed in patients with type 2 diabetes mellitus (T2DM). Atrial fibrillation (AF) and atrial flutter have been more pronounced in patients with hyperglycemia. Sodium-glucose co-transporter 2 (SGLT2) inhibitors are now considered as second-line treatment for patients with T2DM following inadequate glycemic control with first line agents.
View Article and Find Full Text PDFEfficacy and safety of atrial fibrillation ablation in patients with aged 80 years or older. Letter to the editor (response to Kataoka N, et al.).
Heart Vessels
January 2025
Department of Cardiovascular Medicine, Nippon Medical School, 1-1-5, Sendagi, Bunkyo-Ku, Tokyo, 113-8603, Japan.
Transcardiac gradients of pro-cholecystokinin, cholecystokinin, and gastrin in patients with and without heart failure with reduced ejection fraction.
Peptides
January 2025
Department of Cardiology, Rigshospitalet, Copenhagen, Denmark, Department of Clinical Medicine, University of Copenhagen, Denmark.
Background: Cholecystokinin (CCK) is secreted from the intestines in response to food intake. We previously reported that the CCK gene is also expressed in the mammalian heart, and it has been hypothesized that proCCK could be a novel cardiac biomarker. However, it is not known whether cardiac gene expression leads to secretion in humans.
View Article and Find Full Text PDFNet Benefit of Early Anticoagulation for Stroke With Atrial Fibrillation: Post Hoc Analysis of the ELAN Randomized Clinical Trial.
JAMA Netw Open
January 2025
Department of Neurology, Inselspital, Bern University Hospital and University of Bern, Bern, Switzerland.
Importance: The net clinical effect of early vs later direct oral anticoagulant (DOAC) initiation after atrial fibrillation-associated ischemic stroke is unclear.
Objective: To investigate whether early DOAC treatment is associated with a net clinical benefit (NCB).
Design, Setting, And Participants: This was a post hoc analysis of the Early Versus Late Initiation of Direct Oral Anticoagulants in Post-Ischaemic Stroke Patients With Atrial Fibrillation (ELAN) open-label randomized clinical trial conducted across 103 sites in 15 countries in Europe, the Middle East, and Asia between November 6, 2017, and September 12, 2022, with a 90-day follow-up.
Left atrial appendage velocity, association with inflammatory indices in non-valvular atrial fibrillation patients.
Future Cardiol
January 2025
Echocardiography research Center, Rajaie cardiovascular medical and research Center, Iran University of Medical Science, Tehran, Iran.
Introduction: Decreased left atrial appendage emptying velocity (LAAV) is a marker for thrombus formation. This study evaluates the association between LAAV and inflammatory indices in non-valvular atrial fibrillation (AF) patients.
Methods: The study population was 1428 patients with AF, 875 of whom enrolled.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!